** Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080
** Stock posts its biggest intraday pct gain since July 2023
** Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million
** FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample
** Agreement signed with Hong Kong-headquartered PHASE Scientific International
** About 15.8 million shares change hands, compared with the 30-day average volume of 663,247
** YTD, shares up 108.6%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。